Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474.
Maria-João BonifácioFilipa SousaCátia AiresAna I LoureiroCarlos Fernandes-LopesNuno M PiresPedro Nuno PalmaPaul MoserPatricio Soares-Da-SilvaPublished in: British journal of pharmacology (2020)
BIA 10-2474 potently inhibits FAAH in vivo, similarly to PF-04457845 and interacts with a number of lipid processing enzymes, some previously identified in human cells as off-targets particularly at high levels of exposure. These interactions occurred at doses used in toxicology studies, but the implication of these off-targets in the clinical trial accident remains unclear.